<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01772875</url>
  </required_header>
  <id_info>
    <org_study_id>BLLAV-1</org_study_id>
    <nct_id>NCT01772875</nct_id>
  </id_info>
  <brief_title>Bladder Lavage as Decontamination Method for Asymptomatic Bacteriuria With Uropathogens in Catheterized Patients</brief_title>
  <official_title>Pilot Study to Evaluate the Efficacy of Antiseptic Bladder Lavage Versus Pulsatile Lavage With Physiologic Serum in Catheterized Patients With Asymptomatic Bacteriuria With Uropathogens.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Multiple Sclerosis Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Multiple Sclerosis Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In patients with advanced multiple sclerosis, permanent urinary catheters are often used to
      manage the urinary incontinence and bladder emptying problems. These catheters will lead to
      urinary tract infection, blocking of the catheter etc.. Especially infections with certain
      bacteria such as proteus, enterobacteriaceae and ESBL producing enterobacteriaceae and
      pseudomonas can pose a problem for the hospital infection control and for the patient.

      This study wants to evaluate the potential role of regular bladder lavage with saline, a
      solution of betadine, an acid solution of acetic acid and of URotainer Twin Suby G ( Braun)in
      the decontamination of these bladders and the prevention of clinically relevant urinary tract
      infections.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PAtients will be selected from the catheterised patient population of the National MS Center
      in Belgium for this prospective randomised comparative pilot studyon bladder lavage.

      The potential benefit for the patient is a reduction in number of clinical urinary tract
      infections and a reduction of antibiotic use.

      According to the type of bacteria that is cultured from the urine, patients will be allocated
      to one of 4 subgroups:

        -  30 patients will recieve bladder lavage with a Isobetadine Dermicum Solution

        -  20 patients will revieve bladder lavage with acetic acid solutions

        -  10 patients will recieve bladder lavage with saline

        -  10 patients will receive bladder lavage with Urotainer Suby G

      The effect will be measured by two repeat urine cultures after the bladder lavage( 2days and
      5 days).

      From a safety perspective and to assess the irritation caused by the lavage, white blood cell
      counts in the urine will be done.

      Adverse events will be monitored according to GCP regulations.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">August 2014</completion_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>urinary culture</measure>
    <time_frame>day 2 and day 5 after last bladder lavage</time_frame>
    <description>After 5 consecutive days of bladder lavage, a urine culture will be taken at day 2 and 5. A count of &lt;100.000 CFU/ml and is considered a positive result.
The outcome will be considered positive if this positive result is found in more than 30% of subjects.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>pyuria</measure>
    <time_frame>day 2 and day 5 after the last bladder lavage</time_frame>
    <description>changes in white blood cell count are monitored at day 2 and 5 afte 5 consecutive days of bladder lavage. This is an assessment of bladder irritation.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Catheter Related Infections</condition>
  <arm_group>
    <arm_group_label>lavage Isobetadine Dermicum solution</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient will receive 1 bladder lavage daily with a solution of 5ml Isobetadine Dermicum in 100cc saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>lavage Acetic Acid solution</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive a daily bladder lavage during 5 consecutive days with a solution of 0.5% acetic acid in 100cc of saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>lavage with saline</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>patients will receive during 5 consecutive days a bladder lavage with 100cc saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>lavage Urotainer Suby G</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients will receive during 5 consecutive days a bladder lavage with 100cc of Urotainer Suby G</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>bladder lavage</intervention_name>
    <description>the bladder is rinced through the urinary catheter with the lavage solution</description>
    <arm_group_label>lavage Isobetadine Dermicum solution</arm_group_label>
    <arm_group_label>lavage Acetic Acid solution</arm_group_label>
    <arm_group_label>lavage with saline</arm_group_label>
    <arm_group_label>lavage Urotainer Suby G</arm_group_label>
    <other_name>bladder rincing</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with an indwelling catheter

          -  catheter associated bacteriuria with proteus, enterobacteriaceae or pseudomonas

          -  willing and able to give informed consent to the study

        Exclusion Criteria:

          -  patients with a clinically relevant UTI ( fever, pain or cloudy urine)

          -  cognitively impaired patients

          -  patients not able or willing to give informed consent

          -  patients with allergies for ISobetadine dermicum or other substances used in the
             protocol

          -  patients who only have a catheter for less than 1 month

          -  patients taking systemic antibiotics during the last 48h
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dirk De Ridder, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National MS Center Belgium &amp; University Hospitals KU Leuven</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dirk De Ridder, PRof.</last_name>
    <phone>+32-16-346930</phone>
    <email>dirk.deridder@uzleuven.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Corinne Cuveliers, RN</last_name>
    <phone>+32-2-5978801</phone>
    <email>corinne.cuveliers@mscenter.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National MS Center</name>
      <address>
        <city>Steenokkerzeel</city>
        <state>Vlaams-Brabant</state>
        <zip>1820</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dirk De Ridder, Prof.</last_name>
      <email>dirk.deridder@uzleuven.be</email>
    </contact>
    <contact_backup>
      <last_name>Corinne Cuvelier, RN</last_name>
      <email>corinne.cuvelier@mscenter.be</email>
    </contact_backup>
    <investigator>
      <last_name>Dirk De Ridder, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <link>
    <url>http://www.mscenter.be</url>
    <description>website of the National MS Center, Belgium</description>
  </link>
  <reference>
    <citation>Jaggi N, Sissodia P. Multimodal supervision programme to reduce catheter associated urinary tract infections and its analysis to enable focus on labour and cost effective infection control measures in a tertiary care hospital in India. J Clin Diagn Res. 2012 Oct;6(8):1372-6. doi: 10.7860/JCDR/2012/4229.2362.</citation>
    <PMID>23205350</PMID>
  </reference>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 17, 2013</study_first_submitted>
  <study_first_submitted_qc>January 18, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 21, 2013</study_first_posted>
  <last_update_submitted>January 18, 2013</last_update_submitted>
  <last_update_submitted_qc>January 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 21, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Multiple Sclerosis Center</investigator_affiliation>
    <investigator_full_name>Prof. dr. Dirk De Ridder</investigator_full_name>
    <investigator_title>medical director</investigator_title>
  </responsible_party>
  <keyword>urinary catheter</keyword>
  <keyword>UTI</keyword>
  <keyword>bladder lavage</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bacteriuria</mesh_term>
    <mesh_term>Catheter-Related Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

